Trial Profile

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Itolizumab (Primary) ; Corticosteroids
Indications Graft-versus-host disease
Focus Adverse reactions; Therapeutic Use
Acronyms EQUATE
Sponsors Equillium

Most Recent Events

07 Mar 2023 Status changed from recruiting to completed.
17 Feb 2023 According to an Equillium media release, the oral presentation at the Tandem Meetings of ASTCT and CIBMTRis available on the Presentations page of Equilliums website.
17 Feb 2023 According to an Equillium media release, results from this study presented as oral Presentation at the Tandem Meetings of ASTCT and CIBMTR

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com